MeSH term
Frequency | Condition_Probility | Humans | 434 | 0.0 |
Prevalence | 2 | 0.0 |
Adult | 169 | 0.0 |
Australia | 4 | 2.0 |
Female | 228 | 0.0 |
Glutathione Transferase/*genetics | 169 | 25.0 |
Male | 274 | 0.0 |
*Polymorphism, Genetic | 114 | 2.0 |
Research Support, Non-U.S. Gov't | 288 | 0.0 |
Risk Factors | 79 | 1.0 |
Smoking/adverse effects | 20 | 6.0 |
Ultraviolet Rays/adverse effects | 3 | 4.0 |
Adolescent | 42 | 0.0 |
Child | 31 | 0.0 |
Child, Preschool | 20 | 0.0 |
Follow-Up Studies | 9 | 0.0 |
Gene Frequency | 38 | 0.0 |
Genotype | 174 | 1.0 |
Infant | 13 | 0.0 |
Infant, Newborn | 6 | 0.0 |
Isoenzymes/genetics | 50 | 15.0 |
Prognosis | 18 | 0.0 |
Acute Disease | 2 | 0.0 |
Case-Control Studies | 106 | 2.0 |
Cytochrome P-450 Enzyme System/genetics/metabolism | 3 | 6.0 |
Disease Susceptibility/enzymology | 2 | 40.0 |
Polymorphism, Genetic/*genetics | 22 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 111 | 0.0 |
Alleles | 32 | 0.0 |
Cell Transformation, Neoplastic/genetics | 3 | 1.0 |
*DNA Methylation | 80 | 12.0 |
DNA, Neoplasm/chemistry/genetics | 2 | 1.0 |
Gene Expression Profiling | 4 | 0.0 |
*Gene Expression Regulation, Neoplastic | 11 | 0.0 |
*Gene Silencing | 8 | 4.0 |
*Genes, Tumor Suppressor | 9 | 0.0 |
Polymerase Chain Reaction | 79 | 0.0 |
Promoter Regions (Genetics)/*genetics | 11 | 1.0 |
Tumor Cells, Cultured | 27 | 0.0 |
*Tumor Suppressor Proteins | 10 | 0.0 |
Aged | 139 | 0.0 |
Aged, 80 and over | 60 | 0.0 |
Amino Acid Substitution | 4 | 0.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
Base Sequence | 34 | 0.0 |
Continental Population Groups/genetics | 3 | 3.0 |
DNA Primers | 18 | 0.0 |
Isoenzymes/*genetics | 70 | 16.0 |
Middle Aged | 208 | 0.0 |
Neoplasm Metastasis | 3 | 0.0 |
*Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Retrospective Studies | 5 | 0.0 |
Survival Analysis | 7 | 0.0 |
Time Factors | 14 | 0.0 |
Carcinoma, Squamous Cell/*genetics/mortality/pathology | 2 | 14.0 |
Cytochrome P-450 Enzyme System/*genetics | 8 | 1.0 |
DNA Mutational Analysis | 8 | 0.0 |
Disease-Free Survival | 3 | 0.0 |
English Abstract | 18 | 0.0 |
Gene Expression Regulation, Neoplastic/physiology | 3 | 2.0 |
Neoplasm Staging | 16 | 0.0 |
Survival Rate | 11 | 0.0 |
*Cell Cycle Proteins | 6 | 0.0 |
Comparative Study | 64 | 0.0 |
Glutathione Transferase/metabolism | 7 | 0.0 |
Isoenzymes/metabolism | 6 | 1.0 |
*Promoter Regions (Genetics) | 18 | 0.0 |
Protein p16/metabolism | 2 | 3.0 |
Transcription Factors/metabolism | 3 | 0.0 |
Pharmacogenetics | 5 | 4.0 |
Polymorphism, Genetic | 55 | 1.0 |
*Genetic Predisposition to Disease | 36 | 3.0 |
Linkage Disequilibrium | 2 | 0.0 |
*Polymorphism, Single Nucleotide | 4 | 0.0 |
Occupational Exposure/*adverse effects | 2 | 2.0 |
Oxidoreductases/*genetics | 2 | 2.0 |
Polymorphism, Genetic/genetics | 8 | 1.0 |
Carcinogens/metabolism | 4 | 12.0 |
DNA Repair/genetics | 2 | 1.0 |
Genes, BRCA1 | 2 | 1.0 |
Variation (Genetics) | 6 | 0.0 |
Lipid Peroxidation | 2 | 1.0 |
Maternal-Fetal Exchange | 2 | 1.0 |
Metabolic Detoxication, Drug | 6 | 7.0 |
Phenotype | 16 | 0.0 |
Pregnancy | 8 | 0.0 |
Cytochrome P-450 CYP1A1/*genetics | 11 | 6.0 |
*DNA Adducts | 4 | 11.0 |
Lymphocytes/drug effects | 3 | 4.0 |
Occupational Exposure | 5 | 6.0 |
Age Factors | 13 | 0.0 |
Genes, p53 | 5 | 1.0 |
Genetic Predisposition to Disease/*genetics | 5 | 1.0 |
Lung Neoplasms/*genetics | 9 | 3.0 |
Models, Genetic | 3 | 0.0 |
Polymorphism, Restriction Fragment Length | 29 | 1.0 |
Adenocarcinoma/diagnosis/*genetics | 2 | 50.0 |
DNA Methylation | 17 | 2.0 |
Diagnosis, Differential | 3 | 0.0 |
Gene Expression Regulation, Enzymologic | 7 | 0.0 |
Gene Expression Regulation, Neoplastic | 14 | 0.0 |
Genetic Predisposition to Disease/genetics | 8 | 1.0 |
Immunohistochemistry | 13 | 0.0 |
Promoter Regions (Genetics)/genetics | 9 | 0.0 |
Prostatic Hyperplasia/diagnosis/genetics | 2 | 100.0 |
Prostatic Neoplasms/diagnosis/*genetics | 2 | 40.0 |
Tumor Markers, Biological/genetics | 8 | 8.0 |
DNA, Neoplasm/genetics | 6 | 0.0 |
Glutathione Transferase/*biosynthesis/*genetics | 2 | 100.0 |
Promoter Regions (Genetics) | 24 | 0.0 |
Prostatic Neoplasms/*enzymology/pathology | 2 | 18.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 18 | 0.0 |
Biopsy | 4 | 0.0 |
Cell Transformation, Neoplastic | 6 | 1.0 |
Disease Progression | 8 | 0.0 |
Transcription, Genetic | 11 | 0.0 |
Acyltransferases/*genetics | 17 | 39.0 |
DNA, Neoplasm | 4 | 3.0 |
Odds Ratio | 30 | 2.0 |
Blotting, Northern | 2 | 0.0 |
*CpG Islands | 7 | 8.0 |
Glutathione Transferase/genetics/metabolism | 7 | 5.0 |
Immunoblotting | 2 | 0.0 |
Luciferases/metabolism | 2 | 0.0 |
Methylation | 9 | 1.0 |
Protein Binding | 5 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 15 | 0.0 |
*Transcription, Genetic | 4 | 0.0 |
Transfection | 13 | 0.0 |
DNA-Binding Proteins/genetics | 5 | 0.0 |
Genes, p16 | 3 | 3.0 |
Lung Neoplasms/enzymology/etiology/*genetics | 4 | 100.0 |
DNA Adducts/*metabolism | 6 | 13.0 |
Genetic Predisposition to Disease | 37 | 1.0 |
Glutathione Transferase/genetics | 44 | 14.0 |
Polycyclic Hydrocarbons, Aromatic/*metabolism | 3 | 16.0 |
DNA Primers/chemistry | 11 | 0.0 |
Prostatic Neoplasms/*genetics | 8 | 4.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Blotting, Western | 3 | 0.0 |
CpG Islands/*genetics | 13 | 13.0 |
DNA, Neoplasm/genetics/metabolism | 2 | 2.0 |
Gene Expression Regulation, Enzymologic/drug effects | 3 | 1.0 |
Gene Expression Regulation, Neoplastic/drug effects | 3 | 0.0 |
Glutathione Transferase/*genetics/metabolism | 20 | 26.0 |
Isoenzymes/*genetics/metabolism | 7 | 11.0 |
Breast Neoplasms/*enzymology | 2 | 3.0 |
Cytochrome P-450 CYP1A1/genetics | 17 | 17.0 |
DNA Adducts/*analysis | 3 | 6.0 |
DNA, Neoplasm/analysis | 4 | 0.0 |
Homozygote | 9 | 0.0 |
NAD(P)H Dehydrogenase (Quinone)/*genetics | 3 | 4.0 |
Acetylation | 4 | 0.0 |
Asthma/*chemically induced/genetics | 2 | 100.0 |
Isocyanates/*adverse effects | 2 | 66.0 |
Chromosomes, Human, Pair 11/*genetics | 4 | 1.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Microsatellite Repeats | 2 | 0.0 |
Acetyltransferases/*genetics | 3 | 5.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 3 | 0.0 |
DNA Repair/*genetics | 4 | 1.0 |
Disease Susceptibility | 8 | 1.0 |
Treatment Outcome | 8 | 0.0 |
Xenobiotics/metabolism | 3 | 6.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
*Environment | 2 | 4.0 |
Glutathione Transferase/biosynthesis/genetics | 2 | 14.0 |
Lung Neoplasms/enzymology/*genetics | 3 | 8.0 |
Multivariate Analysis | 8 | 0.0 |
Oxidation-Reduction | 5 | 0.0 |
Cell Count | 2 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
Cytosol/chemistry/enzymology | 2 | 33.0 |
Hydrogen Peroxide/toxicity | 2 | 8.0 |
In Vitro | 2 | 0.0 |
Isoenzymes/biosynthesis/genetics | 2 | 4.0 |
Comet Assay | 4 | 5.0 |
Cotinine/urine | 2 | 28.0 |
DNA Adducts | 3 | 4.0 |
*DNA Damage | 12 | 2.0 |
Exons | 9 | 0.0 |
*Occupational Exposure | 16 | 11.0 |
Smoking | 16 | 4.0 |
DNA, Neoplasm/*analysis | 4 | 2.0 |
Polymerase Chain Reaction/methods | 11 | 0.0 |
Tumor Markers, Biological/analysis | 3 | 0.0 |
CpG Islands | 16 | 5.0 |
Glutathione Transferase/biosynthesis/*genetics | 5 | 71.0 |
Isoenzymes/biosynthesis/*genetics | 3 | 16.0 |
Mutation | 16 | 0.0 |
Prostatic Neoplasms/*genetics/metabolism | 2 | 5.0 |
Glutathione Transferase/*genetics/*metabolism | 2 | 15.0 |
Prostatic Neoplasms/*genetics/*pathology | 3 | 13.0 |
Sensitivity and Specificity | 21 | 0.0 |
Acyltransferases/genetics | 7 | 43.0 |
CpG Islands/genetics | 5 | 3.0 |
Lung Neoplasms/etiology/*genetics | 3 | 11.0 |
Glucuronosyltransferase/metabolism | 2 | 7.0 |
Pharmaceutical Preparations/*metabolism | 2 | 2.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/genetics | 9 | 37.0 |
Gene Expression | 7 | 0.0 |
O(6)-Methylguanine-DNA Methyltransferase/genetics | 12 | 42.0 |
Protein p16/genetics | 7 | 8.0 |
Receptors, Retinoic Acid/genetics | 12 | 13.0 |
Transcription Factors/genetics | 3 | 0.0 |
Confidence Intervals | 8 | 2.0 |
Genetic Markers | 11 | 0.0 |
Logistic Models | 13 | 1.0 |
Risk | 9 | 1.0 |
Genes, Tumor Suppressor | 10 | 1.0 |
DNA/genetics | 5 | 0.0 |
Epidemiologic Studies | 3 | 6.0 |
Postmenopause | 3 | 1.0 |
Animals | 11 | 0.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Mice | 2 | 0.0 |
Cadherins/genetics | 10 | 18.0 |
Neoplasm Proteins/genetics | 5 | 1.0 |
*Ubiquitin-Protein Ligases | 2 | 0.0 |
Arylamine N-Acetyltransferase/genetics/metabolism | 3 | 20.0 |
Biotransformation | 7 | 1.0 |
Cell Line | 8 | 0.0 |
Chromatography, High Pressure Liquid | 8 | 0.0 |
Kinetics | 5 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Temperature | 2 | 0.0 |
*Diet | 6 | 2.0 |
*Fruit | 2 | 18.0 |
Glutathione Transferase/*genetics/pharmacology | 7 | 63.0 |
*Vegetables | 3 | 23.0 |
*Chromosome Aberrations | 5 | 0.0 |
DNA Repair | 4 | 0.0 |
Population Surveillance | 2 | 1.0 |
Sister Chromatid Exchange | 2 | 4.0 |
Adenocarcinoma/*genetics | 4 | 2.0 |
Breast Neoplasms/*genetics | 4 | 0.0 |
Reference Values | 13 | 0.0 |
Lymphoma/*genetics | 2 | 4.0 |
Genetics, Population | 3 | 0.0 |
Asthma/*genetics | 2 | 3.0 |
Immunoglobulin E/blood | 2 | 1.0 |
*Polymerase Chain Reaction | 2 | 0.0 |
Organ Specificity | 3 | 0.0 |
Breast Neoplasms/*epidemiology/*genetics | 2 | 5.0 |
Codon | 2 | 0.0 |
Heterozygote Detection | 3 | 0.0 |
Glutathione Transferase/chemistry/*genetics | 3 | 25.0 |
Russia | 2 | 2.0 |
Japan | 6 | 0.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
RNA, Neoplasm/genetics/metabolism | 2 | 1.0 |
Restriction Mapping | 3 | 0.0 |
Biological Markers/urine | 2 | 3.0 |
Coke/*adverse effects | 2 | 33.0 |
Metallurgy | 2 | 15.0 |
Biological Markers/analysis | 2 | 0.0 |
Catalysis | 2 | 0.0 |
Glutathione Transferase/genetics/*metabolism | 4 | 28.0 |
Isoenzymes | 5 | 2.0 |
Epoxide Hydrolases/genetics | 4 | 30.0 |
China | 5 | 1.0 |
Chronic Disease | 7 | 0.0 |
Chromosome Aberrations | 7 | 1.0 |
Risk Assessment | 12 | 1.0 |
Glutathione Transferase/*biosynthesis/genetics | 4 | 44.0 |
Precancerous Conditions/pathology | 2 | 9.0 |
Prostatectomy | 2 | 2.0 |
Prostatic Intraepithelial Neoplasia/pathology | 2 | 66.0 |
Glutathione Transferase/*urine | 2 | 100.0 |
Isoenzymes/*urine | 2 | 66.0 |
Biological Markers | 7 | 0.0 |
Cytochrome P-450 CYP2E1/genetics | 5 | 13.0 |
Enzymes/*genetics/metabolism | 2 | 22.0 |
Styrene/*adverse effects/metabolism | 2 | 100.0 |
Analysis of Variance | 6 | 0.0 |
Ascorbic Acid/blood | 2 | 14.0 |
Oxidative Stress | 6 | 1.0 |
Carcinoma, Basal Cell/*genetics | 2 | 14.0 |
Skin Neoplasms/*genetics | 2 | 1.0 |
Carcinoma, Squamous Cell/epidemiology/*genetics | 4 | 23.0 |
Oxidative Stress/genetics | 2 | 8.0 |
*Arylamine N-Acetyltransferase | 2 | 18.0 |
Loss of Heterozygosity | 8 | 0.0 |
*Mutation | 5 | 0.0 |
Polymorphism, Single-Stranded Conformational | 4 | 0.0 |
Proteins/*genetics | 2 | 0.0 |
Genes, Tumor Suppressor/genetics | 2 | 1.0 |
Lung Neoplasms/*genetics/pathology | 2 | 2.0 |
Oncogenes | 2 | 0.0 |
Protein p53/genetics | 3 | 1.0 |
Microsatellite Repeats/genetics | 3 | 0.0 |
Adenocarcinoma/genetics | 2 | 2.0 |
Genes, APC | 2 | 2.0 |
Prostatic Neoplasms/*diagnosis/*genetics | 4 | 57.0 |
Breast Neoplasms/*genetics/pathology | 2 | 0.0 |
Asia/epidemiology | 2 | 12.0 |
Incidence | 8 | 0.0 |
European Continental Ancestry Group | 7 | 1.0 |
*Genotype | 5 | 2.0 |
Age of Onset | 3 | 0.0 |
DNA Primers/genetics | 6 | 0.0 |
Glutathione Transferase/deficiency/*genetics | 2 | 22.0 |
Sequence Deletion | 4 | 0.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Genetic Vectors | 2 | 0.0 |
*Nuclear Proteins | 2 | 0.0 |
Cytochrome P-450 Enzyme System/genetics | 4 | 3.0 |
Epoxide Hydrolases/*genetics | 12 | 37.0 |
Azacitidine/analogs & derivatives/pharmacology | 2 | 8.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Hela Cells | 5 | 0.0 |
Molecular Sequence Data | 17 | 0.0 |
Plasmids/genetics | 2 | 0.0 |
Apoptosis/drug effects | 2 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Lung/*cytology | 2 | 6.0 |
Necrosis | 3 | 0.0 |
Tobacco Smoke Pollution/*adverse effects | 3 | 9.0 |
England | 2 | 1.0 |
Cell Line, Tumor | 6 | 0.0 |
Glutathione Transferase | 2 | 4.0 |
Gene Silencing | 8 | 2.0 |
Neoplasms/*genetics | 5 | 1.0 |
Prostatic Hyperplasia/genetics | 2 | 10.0 |
Age Distribution | 2 | 0.0 |
Cohort Studies | 12 | 0.0 |
Genetic Predisposition to Disease/*epidemiology | 2 | 8.0 |
*Acid Anhydride Hydrolases | 3 | 1.0 |
Genes, p16/genetics | 2 | 9.0 |
Proteins/metabolism | 2 | 0.0 |
Glutathione Transferase/*metabolism | 7 | 21.0 |
Isoenzymes/*metabolism | 5 | 1.0 |
*Oxidative Stress | 3 | 1.0 |
Prostate/metabolism | 2 | 2.0 |
Atrophy | 3 | 2.0 |
DNA Damage | 4 | 0.0 |
Prostate/pathology | 2 | 8.0 |
Prostatic Intraepithelial Neoplasia/genetics | 2 | 66.0 |
United States/epidemiology | 3 | 0.0 |
Arylamine N-Acetyltransferase/genetics | 5 | 8.0 |
Carcinogens/*metabolism | 2 | 2.0 |
Cytochrome P-450 CYP2D6/genetics | 4 | 12.0 |
Environmental Exposure | 2 | 1.0 |
Menopause | 2 | 0.0 |
*Aryl Hydrocarbon Hydroxylases | 4 | 0.0 |
Bronchi/*metabolism | 2 | 6.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Leukocytes | 2 | 3.0 |
Statistics, Nonparametric | 2 | 0.0 |
Acyltransferases/metabolism | 2 | 15.0 |
Blotting, Southern | 2 | 0.0 |
Receptors, Retinoic Acid/metabolism | 2 | 2.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Binding Sites | 5 | 0.0 |
DNA-Binding Proteins/metabolism | 4 | 0.0 |
K562 Cells | 2 | 0.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Dinitrochlorobenzene/metabolism | 4 | 44.0 |
Carcinoma, Non-Small-Cell Lung/*genetics | 3 | 4.0 |
Tissue Inhibitor of Metalloproteinase-3/genetics | 5 | 35.0 |
Biological Markers/*analysis | 2 | 1.0 |
Recurrence | 2 | 0.0 |
*Steroid 16-alpha-Hydroxylase | 2 | 1.0 |
DNA/metabolism | 4 | 0.0 |
Prostatic Neoplasms/*genetics/metabolism/pathology | 2 | 7.0 |
Tumor Suppressor Proteins/genetics | 6 | 8.0 |
Neoplasm Proteins/*genetics | 6 | 0.0 |
Epithelium/pathology | 2 | 1.0 |
Catechol O-Methyltransferase/*genetics | 2 | 2.0 |
Cells, Cultured | 6 | 0.0 |
Rats | 2 | 0.0 |
Genetic Predisposition to Disease/epidemiology | 5 | 5.0 |
Apoptosis | 2 | 0.0 |
Cisplatin/pharmacology | 2 | 1.0 |
Drug Resistance, Neoplasm | 4 | 0.0 |
Flow Cytometry | 2 | 0.0 |
European Continental Ancestry Group/genetics | 5 | 0.0 |
Prostatic Neoplasms/etiology/*genetics | 2 | 28.0 |
Exons/genetics | 6 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Polymerase Chain Reaction/*methods | 5 | 0.0 |
Chi-Square Distribution | 4 | 0.0 |
Oxidative Stress/*genetics | 2 | 7.0 |
Life Style | 2 | 1.0 |
Lung Neoplasms/*etiology/genetics | 2 | 20.0 |
Polycyclic Hydrocarbons, Aromatic/*adverse effects | 2 | 18.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
Lung Neoplasms/epidemiology/*genetics | 2 | 14.0 |
Smoking/epidemiology | 3 | 4.0 |
DNA Adducts/*blood | 2 | 18.0 |
Metabolic Detoxication, Drug/genetics | 2 | 10.0 |
Poland | 3 | 2.0 |
Seasons | 2 | 1.0 |
Cyclin D1/*genetics | 2 | 3.0 |
Neoplasms, Multiple Primary/*genetics | 2 | 5.0 |
Occupations | 2 | 14.0 |
Hybrid Cells | 2 | 0.0 |
Catechol O-Methyltransferase/genetics | 2 | 6.0 |
Linkage (Genetics) | 4 | 0.0 |
*Membrane Transport Proteins | 2 | 0.0 |
Reproducibility of Results | 6 | 0.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Carcinoma, Squamous Cell/*genetics | 3 | 1.0 |
Questionnaires | 4 | 0.0 |
Cytochrome P-450 CYP2E1/*genetics | 5 | 4.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
Heterozygote | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Smoking/genetics | 2 | 10.0 |
Skin Tests | 2 | 1.0 |
Genetic Screening/*methods | 3 | 2.0 |
Asian Continental Ancestry Group/*genetics | 2 | 0.0 |
Probability | 3 | 0.0 |
Antimetabolites, Antineoplastic/*pharmacology | 2 | 2.0 |
Fluorouracil/*pharmacology | 2 | 5.0 |
Forecasting | 3 | 0.0 |
*Gene Expression Profiling | 3 | 0.0 |
*Models, Theoretical | 2 | 3.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Predictive Value of Tests | 6 | 0.0 |
Regression Analysis | 9 | 0.0 |
Stomach Neoplasms/*drug therapy/*genetics | 2 | 100.0 |
African Americans | 2 | 1.0 |
Alcohol Drinking | 2 | 1.0 |
NAD(P)H Dehydrogenase (Quinone)/genetics | 2 | 11.0 |
*Variation (Genetics) | 4 | 0.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Prostatic Neoplasms/enzymology/*genetics | 3 | 18.0 |
Xenobiotics/*metabolism | 3 | 5.0 |
Receptors, Estrogen/analysis | 2 | 0.0 |
Pyrenes/*metabolism | 2 | 14.0 |
Glutathione Peroxidase/*genetics | 2 | 8.0 |
Sex Factors | 5 | 0.0 |
Cytochrome P-450 CYP1A1/genetics/metabolism | 2 | 6.0 |
Cross-Sectional Studies | 2 | 0.0 |
Isoenzymes/blood/genetics | 3 | 17.0 |
Models, Biological | 2 | 0.0 |
Tumor Markers, Biological/*metabolism | 2 | 0.0 |
Carcinogens/toxicity | 2 | 3.0 |
Acetyltransferases/genetics | 3 | 8.0 |
Cytochrome P-450 CYP1A1/*genetics/metabolism | 3 | 13.0 |
Leukocytes/enzymology | 2 | 1.0 |
Smoking/*adverse effects | 10 | 4.0 |
Microsomes/*enzymology | 2 | 4.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 3 | 0.0 |
Italy/epidemiology | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Air Pollutants, Occupational/toxicity | 2 | 100.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
Down-Regulation | 2 | 0.0 |
Arylamine N-Acetyltransferase/*genetics | 7 | 3.0 |
Colorectal Neoplasms/*genetics | 2 | 0.0 |
Pulmonary Disease, Chronic Obstructive/*enzymology/*genetics | 2 | 66.0 |
Taiwan | 2 | 1.0 |
Kidney Neoplasms/*genetics | 2 | 0.0 |
Sulfites/pharmacology | 7 | 21.0 |
Styrene/*toxicity | 3 | 42.0 |
Isoenzymes/genetics/metabolism | 4 | 2.0 |
Alcohol Drinking/adverse effects | 4 | 8.0 |
Adenocarcinoma/enzymology/*genetics | 2 | 12.0 |
Prostate/metabolism/pathology | 2 | 10.0 |
Signal Transduction | 2 | 0.0 |
Drug Resistance | 3 | 0.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Colorectal Neoplasms/*enzymology/*genetics | 2 | 18.0 |
Respiratory Function Tests | 2 | 1.0 |
Smoking/*adverse effects/genetics | 2 | 14.0 |
Carcinogens/*toxicity | 2 | 1.0 |
Carcinoma, Squamous Cell/enzymology/*genetics | 4 | 25.0 |
Laryngeal Neoplasms/genetics | 2 | 15.0 |
Pharyngeal Neoplasms/genetics | 2 | 28.0 |
Neoplasms/*etiology | 2 | 7.0 |
Carcinoma, Squamous Cell/*enzymology/genetics | 2 | 22.0 |
Epoxy Compounds/*toxicity | 2 | 10.0 |
Mutagens/toxicity | 2 | 5.0 |
*Chromosomal Proteins, Non-Histone | 2 | 0.0 |
*Repressor Proteins | 2 | 0.0 |
Pilot Projects | 3 | 0.0 |
Genes, p53/*genetics | 2 | 0.0 |
Prostatic Neoplasms/genetics/*pathology | 2 | 10.0 |
Telomerase/physiology | 2 | 20.0 |
Tumor Markers, Biological | 2 | 0.0 |
Coke | 2 | 50.0 |
Mutagenicity Tests | 2 | 1.0 |
Chromatography, High Pressure Liquid/*methods | 2 | 1.0 |
Polymorphism, Single Nucleotide/*genetics | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/*methods | 2 | 3.0 |
Esophageal Neoplasms/enzymology/*genetics | 2 | 40.0 |
Asian Continental Ancestry Group/genetics | 3 | 0.0 |
Acid Anhydride Hydrolases/genetics | 2 | 28.0 |
Adenomatous Polyposis Coli Protein/genetics | 6 | 37.0 |
Nuclear Proteins/genetics | 3 | 1.0 |
p14ARF Protein/genetics | 5 | 23.0 |
Chromosome Mapping | 4 | 0.0 |
Receptors, Androgen/genetics | 3 | 5.0 |
Adenocarcinoma/enzymology/genetics | 2 | 10.0 |
Multigene Family | 2 | 0.0 |
Micronuclei, Chromosome-Defective/drug effects | 2 | 33.0 |
Mutagens/*toxicity | 2 | 1.0 |
Sister Chromatid Exchange/drug effects | 2 | 10.0 |
Tumor Markers, Biological/*genetics | 5 | 4.0 |
Protein Conformation | 3 | 0.0 |
Transcription Factor AP-1/metabolism | 2 | 0.0 |
DNA Probes | 2 | 0.0 |
Biopsy, Needle | 3 | 0.0 |
African Continental Ancestry Group/genetics | 3 | 1.0 |
*Gene Frequency | 2 | 0.0 |
Lung/*enzymology | 2 | 3.0 |
Enzymes/*genetics | 2 | 4.0 |
Lung | 2 | 2.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Glutathione Transferase/*biosynthesis | 2 | 20.0 |
Isoenzymes/biosynthesis | 2 | 4.0 |
*Chromosome Mapping | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/genetics | 2 | 8.0 |
DNA/chemistry | 2 | 0.0 |
Smoking/*genetics | 2 | 4.0 |
Smoking/*metabolism | 2 | 4.0 |
Binding, Competitive | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Phosphorylation | 2 | 0.0 |
Glutathione/*metabolism | 3 | 4.0 |
United States | 3 | 0.0 |
Pedigree | 2 | 0.0 |
Syndrome | 2 | 0.0 |
African Continental Ancestry Group | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/genetics | 2 | 1.0 |
*Chromosomes, Human, Pair 11 | 2 | 0.0 |
Prospective Studies | 2 | 0.0 |
Gene Frequency/genetics | 3 | 0.0 |
Enzyme Induction | 2 | 0.0 |
Acyltransferases/*genetics/pharmacology | 2 | 100.0 |
Amino Acid Sequence | 2 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Micronucleus Tests | 2 | 4.0 |
Gastric Mucosa/enzymology | 2 | 15.0 |
Gene Deletion | 4 | 0.0 |
Haplotypes | 2 | 0.0 |
India | 2 | 0.0 |
DNA, Neoplasm/metabolism | 4 | 2.0 |
Alcohol Drinking/*adverse effects | 2 | 5.0 |
DNA/analysis | 2 | 0.0 |
Carcinoma, Small Cell/genetics | 2 | 5.0 |
Mutation, Missense | 2 | 0.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
China/epidemiology | 2 | 1.0 |
Glutathione Transferase/genetics/physiology | 2 | 66.0 |
Isoenzymes/genetics/physiology | 2 | 14.0 |
Variation (Genetics)/genetics | 2 | 1.0 |
Pulmonary Disease, Chronic Obstructive/*genetics | 2 | 50.0 |
Metaplasia | 2 | 2.0 |
Point Mutation | 2 | 0.0 |
Lung Neoplasms/*etiology/*genetics | 3 | 60.0 |
Methylenetetrahydrofolate Reductase (NADPH2) | 4 | 0.0 |
Neoplasms/*genetics/*metabolism | 2 | 40.0 |
Central Nervous System Neoplasms/*genetics | 2 | 14.0 |
Korea | 3 | 1.0 |
Severity of Illness Index | 2 | 0.0 |
Esophageal Neoplasms/epidemiology/*genetics | 2 | 25.0 |
Randomized Controlled Trials | 2 | 0.0 |
Models, Molecular | 2 | 0.0 |
Washington/epidemiology | 2 | 12.0 |
Lymphocytes | 2 | 1.0 |
Cytochrome P-450 CYP2E1/*genetics/pharmacology | 2 | 100.0 |
Stomach Neoplasms/*genetics/pathology | 2 | 4.0 |
Glutathione Transferase/*pharmacology | 2 | 50.0 |
Glutathione Transferase/analysis/*genetics | 2 | 28.0 |
Isoenzymes/analysis/*genetics | 2 | 22.0 |
Glutathione Transferase/blood/*genetics | 3 | 27.0 |
Epoxide Hydrolases/*genetics/pharmacology | 2 | 100.0 |
Forced Expiratory Volume/genetics | 2 | 50.0 |
